Immunotherapy in GU Cancers

Andrea B. Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses challenges with managing toxicities of checkpoint inhibitors for patients with bladder cancer.

Tian Zhang, MD, discusses KEYNOTE-564, as well as the progress that immunotherapy has made in the treatment paradigm of patients with RCC.

The FDA has granted a priority review to a sBLA for use of the combination of nivolumab and ipilimumab as a frontline treatment for intermediate- and poor-risk patients with advanced RCC.

Andrea Apolo, MD, discusses the management of immune-related adverse events in the treatment of bladder cancer.

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the approved checkpoint inhibitors for the second-line treatment of patients with bladder cancer.

In top-line results from the phase III IMmotion151 trial, the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) was associated with a statistically significant reduction in the risk for death or progression in patients with PD-L1

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy trials in renal cell carcinoma.

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the KEYNOTE-564 trial in renal cell carcinoma.

The established efficacy of single-agent checkpoint inhibition for metastatic urothelial carcinoma along with molecule expression analyses suggests that PD-1/PD-L1 inhibition could hold promise for patients with non-muscle invasive bladder cancer, particularly those unresponsive to Bacillus Calmette-Guérin.

The combination of PD-1 or PD-L1 inhibitors with existing frontline therapies could represent a superior approach for some treatment-naïve patients with renal cell carcinoma.

Stemming from the wave of checkpoint inhibitor approvals, multiple trials have begun evaluating immunotherapies in combination with other agents for the treatment of patients with advanced bladder cancer.

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses checkpoint inhibitors in the frontline setting of bladder cancer.

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in renal cell carcinoma (RCC).

Petros Grivas, MD, shares insight on the value of combining immunotherapy regimens in the treatment of patients with urothelial carcinoma.

Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center, discusses novel immunotherapy combinations for patients with bladder cancer.

Maria De Santis, MD, discusses the findings of KEYNOTE-045 and the future of immunotherapy in the treatment landscape of bladder cancer.

Thomas Powles, MD, Barts Cancer Institute, discusses the impact of immunotherapy on the treatment landscape of kidney cancer.

Andrea Necchi, MD, discusses the evolution of bladder cancer therapies, the challenge with the currently available agents, and the next steps and clinical trials being conducted in the field.

An extension in overall survival seen with the combination of nivolumab and ipilimumab has completely changed the standard of care for patients with metastatic renal cell carcinoma.

A wealth of new clinical trial data for immune checkpoint inhibitors has recently been reported for the treatment of patients with metastatic muscle-invasive urothelial carcinoma.

Andrea Necchi, MD, a medical oncologist at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, discusses the impact of PD-1 inhibition in bladder cancer as well as the promise with combination strategies.

Tanya B. Dorff, MD, associate professor of clinical medicine, University of Southern California, discusses current agents available for patients with metastatic castration-resistant prostate cancer (mCRPC).

Matthew Galsky, MD, professor of medicine, hematology and medical oncology, Mount Sinai Hospital, discusses resistance to checkpoint blockade in metastatic bladder cancer.

Petros Grivas, MD, PhD, medical oncologist, Cleveland Clinic, discusses combining chemotherapy and immunotherapy as a treatment approach for patients with bladder cancer.

The combination of the CD122-biased cytokine NKTR-214 and the PD-1 inhibitor nivolumab demonstrated target lesion reductions of 72% for patients with advanced cancers.

Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center discusses biomarkers for immunotherapy in patients with bladder cancer.

Decades of clinical trials exploring modifications of cytotoxic regimens, including the use of different or more drugs, demonstrated that a therapeutic plateau had been reached with conventional chemotherapeutic agents, highlighting the need for novel approaches in urothelial carcinoma.

Andrea Apolo, MD, discusses the combination of cabozantinib plus nivolumab and ipilimumab, as well as the latest data on avelumab in urothelial carcinoma.

The UK’s National Institute for Health and Care Excellence is recommending the use of atezolizumab for treatment-naïve patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-based therapy.

Terence Friedlander, MD, an assistant clinical professor in the Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses checkpoint inhibitors in second-line bladder cancer treatment.